TaylorMade acquires Nassau Golf to expand golf ball business Golf equipment maker makes its first acquisition under Centroid’s ownership
Translated by Ryu Ho-joung 공개 2021-11-10 08:12:09
이 기사는 2021년 11월 10일 08시09분 thebell에 표출된 기사입니다
US-based golf gear maker TaylorMade Golf has acquired Nassau Golf in a move to expand its golf ball operations.The deal, which was announced a week ago without financial details, was the company’s first acquisition after the golf equipment maker was acquired by Seoul-based private equity firm Centroid Investment Partners in August this year.
Founded in 1969, Nassau Golf has grown with its original equipment manufacturing business. Its relationship with TaylorMade began in 2005, with the companies working together to launch the world's first five-piece golf ball in the form of the Penta TP in 2010. Discount retailer Costco’s Kirkland Signature golf balls are also made by Nassau Golf.
TaylorMade entered into discussions to acquire Nassau Golf even before it was bought by Centroid Investment. Nassau Golf recorded a 2.2 billion won ($1.9 million) operating profit on revenue of 33.8 billion won in 2020. Its name will be changed to TM Golf Ball Korea.
The acquisition is expected to help TaylorMade expand its presence in the golf ball market. Globally, TaylorMade holds the largest market share of 24% in the golf equipment market, followed by Callaway (23%) and Titleist (14%). In contrast, its share in the golf ball market only stands at 11%, with the market dominated by Titleist with a 46% share.
“This acquisition further supports TM’s strategic plan to create vertical integration in the company’s golf ball supply chain,” David Abeles, TaylorMade Golf’s chief executive, said.
With Nassau Golf’s plant in Cheongju, North Chungcheong Province, TaylorMade now has golf ball manufacturing facilities in three locations globally, alongside those in Carolina in the US and Taiwan. (Reporting by Se-hun Jo)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [i-point]'자가면역질환 신약' 이노보테라퓨틱스, 미국 임상 1상 '성공적'
- [i-point]폴라리스오피스, 엔비디아 ‘커넥트’ 공식 파트너 선정
- [i-point]신성이엔지, 한국종합기술·다스코와 연료전지 발전사업 협약
- [i-point]신테카바이오, 'PEGS 보스턴 2025' 참가
- [AACR 2025]첫 구두발표 진씨커, 경쟁사 넘보는 '유전자가위 액체생검'
- [AACR 2025]이뮨온시아 'CD47' 안전성 굳히기 "경쟁약과 다르다"
- [AACR 2025]항암 신약 항체 대신 '페라틴', 셀레메디 플랫폼 데뷔전
- [AACR 2025]근거 쌓는 '루닛 스코프' 빅파마 공동연구 쇼케이스
- [변곡점 선 콜마비앤에이치]변화의 마지막 카드, 경영진 교체 '강수' 두나
- [변곡점 선 콜마비앤에이치]속절없는 주가 하락 '트리거', 주가 부양 의지 없었나